Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-synuclein is a presynaptic protein that normally regulates neurotransmitter release and vesicle trafficking, but its pathological aggregation is the hallmark of synucleinopathies such as Parkinson's disease and Dementia with Lewy bodies (UniProt P37840). The transition from soluble monomers to toxic oligomers and insoluble fibrils leads to neuronal dysfunction, impaired proteostasis, and cell death. As a therapeutic target, drug development focuses on preventing the misfolding process, neutralizing toxic extracellular species, or accelerating the clearance of existing aggregates. Current clinical candidates include monoclonal antibodies like Prasinezumab designed to intercept the cell-to-cell spread of pathological protein and small molecules like Anle138b that inhibit oligomer formation. Success in targeting these aggregates is heavily reliant on early detection through emerging biomarkers like seed amplification assays, which can identify misfolded proteins in cerebrospinal fluid before significant neurodegeneration occurs.
Therapeutic strategies include monoclonal antibodies that bind to and promote the clearance of extracellular aggregates, small molecules that inhibit the nucleation and elongation of oligomers, and agents that enhance the lysosomal or autophagic degradation of intracellular protein clumps.
6 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-synuclein aggregate (α-syn).